Journal
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Volume 25, Issue 11, Pages 933-935Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ijnp/pyac042
Keywords
D2/D3 receptor agonism; Parkinson's disease; pramipexole; taste disorders; treatment
Ask authors/readers for more resources
Chemosensory dysfunction, including olfaction and taste, is common in various diseases and the elderly population. It significantly impacts patients' quality of life, yet there is no established treatment for taste disorders. A recent study suggests that pramipexole, a D2/D3 agonist, may be a potential therapeutic target for taste dysfunction, warranting further clinical trials.
Chemosensory (i.e., olfaction and taste) dysfunction is common in neurodegenerative (e.g., Parkinson's disease, Alzheimer's disease, and dementia), psychiatric (e.g., depression, bipolar disorders, other conditions), and postinfectious (i.e., long COVID) diseases and in the elderly. Despite its impact on patients' quality of life, no established treatment for taste disorders exists so far. A recent report on the effect of pramipexole, a D2/D3 agonist, on taste performance in healthy participants provides support for a new potential therapeutic target for taste dysfunction to be tested in future randomized, placebo-controlled, clinical trials across several populations reporting gustatory symptoms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available